glp-1 drugs medicare New coverage Big News for Medicare Part

The EMPA-REG OUTCOMES trial showed that empagliflozin, a SGLT-2i, markedly reduced the risk for HF hospitalization relative to the placebo ( HR = 0.65, 95% CI 0.500.85, P = 0.002) [96]

Preclinical studies have shown that GIP may reduce body weight by reducing food intake and increasing energy consumption, and in combination with GLP-1 receptor agonists, may have a greater effect on patients' blood glucose and body weight

doi: 10.2337/dc19-2251

The DermaVue cascade addresses both problems in sequence

[31] In February 2018, authorization was granted in the European Union, [16] [84] in March 2018 in Japan, [32] and in August 2019 in Australia

These medications offer a promising approach to weight management and blood sugar control